Inflammation and Regeneration

A research team from Osaka Metropolitan University has successfully developed a novel pneumococcal vaccine by combining the team’s proprietary mucosal vaccine technology with pneumococcal surface proteins that can cover a wide range of serotypes. Experiments were conducted using mice and macaques and it was confirmed that pneumonia caused by pneumococcal infection was clearly suppressed in the target groups of animals inoculated with the vaccine.

Scientists review macrophage activation syndrome — a feature of the cytokine storm that kills patients with severe cases of COVID-19, as well as possible treatments.